| European Case Law Identifier: | ECLI:EP:BA:2003:T050001.20031112 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 12 November 2003 | ||||||||
| Case number: | T 0500/01 | ||||||||
| Application number: | 90903576.8 | ||||||||
| IPC class: | C12P 21/08 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Humanized Immunoglobulins and their production and use | ||||||||
| Applicant name: | PROTEIN DESIGN LABS, INC. | ||||||||
| Opponent name: | 02. ICOS Corp. 03. Novartis AG 04. Celltech Therapeutics Ltd 05. Bayer AG 06. Chiron Corporation 08. Genentech, Inc. 09. IDEC Pharmaceuticals Corpn 10. Biotest Pharma GmbH 11. Biotransplant, Inc 12. Bristol-Myers Company 13. GLAXO GROUP LIMITED 14. Boehringer Ingelheim GmbH 17. Schering Corporation 18. Ixsys, Inc |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request and auxiliary request I - added matter (yes) Auxiliary request II - added matter (no), clarity (yes) Remittal - (yes) |
||||||||
| Catchwords: |
According to Article 123(2) EPC, a European patent application or a European patent may not be amended in such a way that it contains subject-matter which extends beyond the content of the application as filed. A claim, the wording of which is essentially identical to a claim as originally filed, can nevertheless contravene the requirements of Article 123(2) EPC, if it contains a feature whose definition has been amended in the description in a non-allowable way. The specific definition of a feature, which according to the description is an overriding requirement of the claimed invention, is applied by a skilled reader to interpret this feature whenever it is mentioned in the patent (see points (11) to (15) of the Reasons for the Decision). |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t010500eu1.html
Date retrieved: 17 May 2021